30.03.2020 Fresenius Medical Care AG & Co. KGaA  DE0005785802

DGAP-News: Fresenius Medical Care AG & Co. KGaA postpones 2020 Annual General Meeting


 

DGAP-News: Fresenius Medical Care AG & Co. KGaA / Key word(s): AGM/EGM
Fresenius Medical Care AG & Co. KGaA postpones 2020 Annual General Meeting

30.03.2020 / 09:01
The issuer is solely responsible for the content of this announcement.


Fresenius Medical Care, the world's leading provider of dialysis products and services, postpones its 2020 Annual General Meeting, which was scheduled for May 19, to a later date this year due to the coronavirus pandemic. The resolutions regarding the allocation of the distributable profit and the payout of the dividend will be postponed accordingly.

As soon as conditions allow again for a reliable planning and safe implementation of the Annual General Meeting, Fresenius Medical Care will announce the new date.

Rice Powell, Chief Executive Officer of Fresenius Medical Care, said: "The decision to postpone our Annual General Meeting was not an easy one for us to take. But the protection and health of our shareholders and employees is very important to us. In light of this exceptional situation, a postponement is the only sensible option."

Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 3.5 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,994 dialysis clinics, Fresenius Medical Care provides dialysis treatments for 345,096 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with the core business, the company focuses on expanding the range of related medical services in the field of Care Coordination. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).

For more information visit the Company's website at www.freseniusmedicalcare.com.

Disclaimer
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.

Contact:
Kontakt:
Dr. Dominik Heger
Head of Investor Relations, Strategic Development & Communications I EVP
[email protected]
Tel. +49 6172 609 2525


30.03.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Fresenius Medical Care AG & Co. KGaA
Else-Kröner-Straße 1
61352 Bad Homburg
Germany
Phone: +49 (0) 6172- 609 2525
Fax: +49 (0) 6172- 609 2301
E-mail: [email protected]
Internet: www.freseniusmedicalcare.com
ISIN: DE0005785802
WKN: 578580
Indices: DAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; NYSE, Luxembourg Stock Exchange
EQS News ID: 1010023

 
End of News DGAP News Service

1010023  30.03.2020 

fncls.ssp?fn=show_t_gif&application_id=1010023&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023
Umsatzerlöse1 17.784,00 16.547,00 17.476,56 17.859,06 17.618,69 19.398,02 19.453,62
EBITDA1,2 3.098,00 3.763,00 3.862,72 4.090,31 3.475,97 3.350,00 3.121,41
EBITDA-Marge3 17,42 22,74 22,10 22,90 19,73 17,27
EBIT1,4 2.362,00 3.038,00 2.269,56 2.304,41 1.852,29 1.511,76 1.369,44
EBIT-Marge5 13,28 18,36 12,99 12,90 10,51 7,79 7,04
Jahresüberschuss1 1.554,00 2.226,00 1.438,50 1.435,83 1.219,03 894,33 732,46
Netto-Marge6 8,74 13,45 8,23 8,04 6,92 4,61 3,77
Cashflow1,7 2.192,00 2.062,00 2.566,95 4.233,16 2.489,50 2.167,38 2.628,80
Ergebnis je Aktie8 4,17 6,47 3,96 3,96 3,31 2,30 1,70
Dividende8 1,06 1,17 1,20 1,34 1,35 1,12 0,96
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2023 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: PricewaterhouseCoopers

INVESTOR-INFORMATIONEN
©boersengefluester.de
Fresenius Medical Care
WKN Kurs in € Einschätzung Börsenwert in Mio. €
578580 36,750 Halten 10.782,94
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
12,89 17,85 0,71 10,35
KBV KCV KUV EV/EBITDA
0,81 4,10 0,55 5,75
Dividende '22 in € Dividende '23 in € Div.-Rendite '23
in %
Hauptversammlung
1,12 1,19 3,24 16.05.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
07.05.2024 30.07.2024 05.11.2024 22.03.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-3,44% 0,37% -3,19% -24,49%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Fresenius Medical Care AG & Co. KGaA  ISIN: DE0005785802 können Sie bei EQS abrufen


Medtech , 578580 , FME , XETR:FME